Who We Are
Vision
Healthcare is one of the world's most complex and rapidly evolving ecosystems. Diverse stakeholders, varying clinical practices, reimbursement systems and policy environments shape healthcare decisions across countries. At the same time, advances in therapeutics, digital health, real-world evidence and artificial intelligence are transforming how healthcare innovations are developed, evaluated, and adopted.
At ETI, we help life sciences, healthcare, and health technology organizations bridge the gap between scientific innovation and real-world patient impact. ETI partners with clients to design, generate, and communicate evidence to enable informed decisions.
Our approach brings together expertise in biostatistics, real-world data and regulatory science to deliver evidence that is scientifically rigorous, strategically relevant and practically executable.
WHAT WE BELIEVE
Evidence must be fit for purpose
Designed to answer the right questions for the right stakeholders at the right time.
Data science must be transparent and auditable
To ensure confidence, reproducibility, and trust in decision-making.
Uncertainty is not a weakness
When appropriately quantified and communicated, it enables stronger decisions and more effective risk management.
WHAT WE DELIVER
Pharma, Biotech, Medical Device and CROs
Evidence Master Plan, Statistical Strategy and Oversight, Regulatory Submission Support
MedTech and Healthtech Innovators
Claim–Evidence Roadmaps, Investor-ready Scientific Narratives, Adoption-readiness Frameworks
Academic Institutions
Courses, Workshops, Capstone Projects
Investors, Boards and Portfolio Management
Independent Scientific Review, Evidence Due Diligence, Scientific Advisory Board Facilitation
WHO WE ARE
Founder
Priya Kulkarni, Ph.D., is a healthcare leader, statistician and evidence strategist with more than 20 years of experience spanning biopharmaceutical development and digital health. . Her experience spans the full product lifecycle—from discovery and development through regulatory approval, launch, and post-market evidence generation—across multiple therapeutic areas and global markets. Throughout her career, Priya has led evidence strategies for some of the industry's most complex and high-impact programs, including breakthrough oncology therapies, drug-device combinations and AI-enabled digital health technologies. She is recognized for her ability to bridge science, strategy, and decision-making.
Priya has held scientific and leadership roles at Genentech, Roche Information Solutions, Merck and Pfizer, partnering with cross-functional teams across clinical development, regulatory affairs, medical affairs, commercial strategy, and health technology innovation. She holds a Ph.D. and M.A. in Statistics from the University of California, Santa Barbara and an M.Sc. in Applied Statistics and Informatics from the Indian Institute of Technology (IIT), Bombay.